Advertisement

Topics

Agilvax Company Profile

20:21 EDT 21st October 2018 | BioPortfolio

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells. TNBC has a high frequency of cancer stem cells, which play a critical role in the high rates of recurrence and poor outcomes in TNBC as compared with other forms of breast cancer. The company’s pipeline and drug discovery platform are based on VLPs derived from RNA bacteriophage that have been engineered to display antigens in an ordered geometric pattern, which can be utilized to stimulate robust and specific immune responses to both foreign pathogens and self-antigens. The Company was founded in 2011 and has headquarters in Albuquerque, New Mexico, and offices in El Paso, Texas.


News Articles [5 Associated News Articles listed on BioPortfolio]

Agilvax Establishes Operations at JLABS @ TMC in Houston

Agilvax, Inc., a biotechnology company developing novel cancer immunotherapies and vaccines, announced today that it is now a resident company at Johnson & Johnson Inno...

Agilvax Awarded $2.3 Million SBIR Fast Track Grant to Advance the Development of AX09 for Triple Negative Breast Cancer

Agilvax, Inc., a biotechnology company developing a novel cancer immunotherapy for the treatment of triple negative breast cancer (TNBC), announced today the receipt of a ...

Agilvax Closes A1 Financing to Expand Pre-IND Studies for AX09 In Triple Negative Breast Cancer

Agilvax, Inc., a biotechnology company that develops targeted cancer immunotherapies and vaccines, has completed a Series A1 financing, which complements the Series A roun...

Agilvax Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12042018] Prices from USD $250

SummaryAgilvax Inc Agilvax is a drug company that discovers and develops vaccines against infectious diseases and immunotherapies to treat cancer. The company develops products based on a proprietary ...

Global Virus Like Particles Market Status and Outlook 20182025 [Report Updated: 15082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynam...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Agilvax

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product,...

Agilvax, Inc.

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, ...

More Information about "Agilvax" on BioPortfolio

We have published hundreds of Agilvax news stories on BioPortfolio along with dozens of Agilvax Clinical Trials and PubMed Articles about Agilvax for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Agilvax Companies in our database. You can also find out about relevant Agilvax Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...


Corporate Database Quicklinks



Searches Linking to this Company Record